Novartis is a Swiss multinational pharmaceutical company.
翻译：诺华是一家瑞士跨国制药公司。
Novartis AG is headquartered in Basel, Switzerland.
翻译：诺华股份有限公司的总部位于瑞士巴塞尔。
Novartis develops and manufactures innovative medicines to improve patient outcomes globally.
翻译：诺华致力于开发和制造创新药物，以改善全球患者的治疗效果。
Novartis recently announced the launch of a new cancer drug that has shown promising results in clinical trials.
翻译：诺华最近宣布推出一款在临床试验中显示出了良好效果的新抗癌药。
The collaboration between Novartis and the research institute aims to accelerate the discovery of new treatments for rare diseases.
翻译：诺华与该研究机构的合作旨在加速罕见病新疗法的发现。
Novartis is committed to sustainability and reducing its environmental footprint.
翻译：诺华致力于可持续发展并减少其对环境的影响。
In 2020, Novartis invested heavily in digital health solutions to enhance patient care.
翻译：2020年，诺华在数字健康解决方案上进行了大量投资，以提升患者护理水平。
Novartis' generics division, Sandoz, produces affordable versions of essential medicines worldwide.
翻译：诺华的仿制药部门山德士在全球范围内生产价格适中的基本药物。
Many of Novartis' drugs have been granted breakthrough therapy designation by the FDA.
翻译：诺华的许多药物已被美国食品药品监督管理局授予突破性疗法认定。
Novartis provides employee training programs to foster a culture of innovation within the organization.
翻译：诺华提供员工培训项目，旨在培养组织内部的创新文化。
Multinational pharmaceutical company Novartis said on Friday it would invest more than 600 million yuan ($84 million) in a new radiopharmaceutical production site to accelerate the introduction of innovative radioligand therapy that will benefit cancer patients in China.
跨国制药公司诺华周五表示，将投资超过6亿元人民币（8400万美元）建设一个新的放射性药物生产基地，以加快引入创新的放射性配体疗法，使中国癌症患者受益。
"China is one of the most strategic markets for Novartis.
“中国是诺华最具战略意义的市场之一。
The company has deep roots in the country, continually investing in and promoting local collaboration and expanding its presence in the China market," said Ingrid Zhang, president and managing director of Novartis China.
诺华中国总裁兼董事总经理Ingrid Zhang表示：“该公司在中国有着深厚的根基，不断投资和促进当地合作，并扩大其在中国市场的影响力。
Upon completion, it will be Novartis' second innovative medicine production site in China.
建成后，它将成为诺华在中国的第二个创新药物生产基地。
Novartis has about 10 radioligand therapy-related products in development, covering a range of oncology diseases.
诺华公司有大约10种放射性配体治疗相关产品正在开发中，涵盖一系列肿瘤疾病。
An innovative medicine for Novartis' targeted radioligand therapy has been approved in the United States and the European Union to treat a type of prostate cancer.
一种用于诺华靶向放射性配体治疗的创新药物已在美国和欧盟获得批准，用于治疗一种类型的前列腺癌症。
Multinational pharma company Novartis said that it would join hands with a PNH patient organization.
跨国制药公司诺华表示，将与PNH患者组织携手合作。
Since 2022, Switzerland-based Novartis has seen 100 percent of its drug development in China achieve simultaneous development with markets worldwide, significantly narrowing the time gap between launches of new drugs in China and globally, said a senior executive of the pharmaceutical company.
总部位于瑞士的诺华制药公司的一位高管表示，自2022年以来，该公司在中国的药物开发100%实现了与全球市场的同步开发，大大缩小了新药在中国和全球上市之间的时间差距。
It was a major breakthrough and the company was quite agile in this respect in the industry, said Shreeram Aradhye, president of global drug development and chief medical officer for Novartis.
诺华公司全球药物开发总裁兼首席医疗官Shreram Aradhye表示，这是一个重大突破，该公司在这方面在行业中相当灵活。
China is one of the priority geographies globally for Novartis, he said, and the company is dedicated to ensuring that it brings high-value medicines to patients to satisfy unmet medical needs.
他说，中国是诺华在全球的优先地区之一，该公司致力于确保为患者带来高价值的药物，以满足未满足的医疗需求。
We have made significant progress in transforming Novartis into a focused pharmaceutical company working in five core therapeutic areas — cardiovascular, immunology, neuroscience, solid tumors and hematology — to bring high-value innovation to patients," said Aradhye.
Aradhye说：“我们在将诺华转变为一家专注于心血管、免疫学、神经科学、实体瘤和血液学五个核心治疗领域的制药公司方面取得了重大进展，为患者带来了高价值的创新。”。
This platform, an outcome of the strategic cooperation between Novartis and Tencent, connects physicians, nurses and patients, supports AI technologies and performs core functions such as daily indicator monitoring, health status assessment and personalized recommendation.
该平台是诺华与腾讯战略合作的成果，连接医生、护士和患者，支持人工智能技术，并执行日常指标监测、健康状况评估和个性化推荐等核心功能。
At Novartis, we strongly support the efforts by the government in this area and are actively working to find ways to support these initiatives.
在诺华，我们强烈支持政府在这一领域的努力，并正在积极努力寻找支持这些举措的方法。
For instance, a blue book regarding fundus diseases, which affect the sight of 30 million people in China, was unveiled at the Novartis booth on Saturday.
例如，一本关于影响中国3000万人视力的眼底病的蓝皮书于周六在诺华展台亮相。
Novartis has also during this CIIE reached a strategic cooperation agreement with Hong Kong C-MER International Eye Care Group (China) Ltd to introduce its innovative drug Beovu, which is used to treat wet age-related macular degeneration, to the Guangdong-Hong Kong-Macao Greater Bay Area.
在本届进博会期间，诺华还与香港C-MER国际眼科护理集团（中国）有限公司达成战略合作协议，将其用于治疗湿性老年性黄斑变性的创新药物Beovu引入广东-香港-马考大湾区。
Dan Brindle, president of Novartis Group (China), said the company has had a strong flow of new drug approvals and therapies or indications included in the national reimbursement drug list to expand patients' accessibility to drugs over the past years.
诺华集团(中国)总裁Dan Brindle表示，过去几年，该公司有大量新药获批，或有疗法和适应症被纳入国家医保药品目录，从而提高了患者获得药物的机会。
During the CIIE, Novartis will display some cutting-edge therapies not yet marketed in China, including a first-in-class small interfering RNA－ribonucleic acid－cholesterol-lowering treatment with only two doses a year.
在进博会期间，诺华将展示一些尚未在中国上市的前沿疗法，包括一款首创的小干扰核糖核酸-胆固醇降低疗法，一年只需接种两次。
Currently, major foreign pharmaceuticals that operate in the ophthalmology market in China include Swiss company Novartis, German firm Bayer, and Irish firm Allergan.
目前在中国眼科市场运营的主要外资药企包括瑞士诺华(Novartis)、德国拜耳(Bayer)及爱尔兰艾尔建(Allergan)。
Wang Yinxiang, chairman and CEO of Jacobio, said the company is the second drug developer in the world to engage in clinical development of an SHP2 inhibitor drug candidate, following Novartis.
Jacobio的董事长兼首席执行官王印祥表示，该公司是继诺华之后世界上第二家从事SHP2抑制剂候选药物临床开发的药物开发商。
Switzerland-based pharmaceutical company Novartis Pharma AG expects to double its sales in China and submit 50 new drug applications in the country by 2024, it announced in its annual financial report released on Tuesday.
瑞士制药巨头诺华制药(Novartis Pharma AG)周二发布的年报显示，该公司预计到2024年在中国的销售额将翻一番，并在中国提交50种新药申请。
"Novartis Oncology and Novartis Pharmaceuticals expect to have seven new products approved in China in 2021.
诺华肿瘤学和诺华制药预计2021年将在中国市场获得七个新产品的批准。
"The Chinese government is becoming increasingly open to innovation and that has enabled Novartis to achieve outstanding performance in the China market.
中国政府正变得越来越开放，支持创新，这使得诺华公司在中国市场取得了卓越的表现。
Novartis claims that it is the second fastest-growing multinational pharmaceutical company in China, which is one of the company's top three markets in the world.
诺华公司声称，它是全球第二大成长速度的跨国制药公司，在中国——该公司全球三大市场之一——增长迅速。
This year's import expo also featured the release of the publication "Expert Recommendations on Improving the Burden of Major Blind-causing Eye Diseases in China" by Novartis Pharmaceuticals and health information consultancy IQVIA.
今年的进博会还见证了诺华制药和健康信息咨询公司IQVIA联合发布的《减轻中国致盲性眼病疾病负担专家建议》出版物。
Around 50 Swiss multinational corporations, including engineering company ABB, pharmaceutical firm Novartis, food and beverage giant Nestle, inspection group SGS as well as small and medium-sized enterprises are participating in the ongoing China International Import Expo in Shanghai from Nov 5 to 10.
包括工程公司ABB、制药企业诺华、食品饮料巨头雀巢、检验集团SGS以及众多中小企业在内，约50家瑞士跨国公司正在参加11月5日至10日在上海举行的中国国际进口博览会。
Dan Brindle, President of Novartis Group, said, "We view the CIIE as an opportunity to connect with stakeholders here to collectively contribute to improving the business environment, help facilitate international exchange and further drive global trade.
诺华集团总裁丹·布林德尔表示：“我们视进博会为一个与各界利益相关方建立联系的平台，共同努力改善商业环境，促进国际交流，并推动全球贸易发展。”
"Novartis is showcasing innovative medicines, breakthrough cell and gene therapies, and a pipeline of products that it plans to bring to China in the near future.
诺华正在展示创新药物、突破性的细胞和基因疗法，以及未来计划引入中国的药品管线。
Switzerland-based Novartis and the World Laureates Association (WLA) also inked a memorandum of understanding of strategic partnership.
瑞士诺华公司和世界杰出科学家协会（WLA）也签署了一份战略合作谅解备忘录。
According to the agreement, the Novartis Shanghai campus will provide office and lab facilities to WLA for the purpose of multidisciplinary cooperation.
根据协议，诺华上海园区将为WLA提供办公和实验室设施，以促进多学科合作。
Foreign firms including the Singapore-listed property developer CapitaLand and Swiss pharmaceutical giant Novartis donated medical supplies like masks, goggles and protective suits to Chinese hospitals.
Vas Narasimhan, CEO of Novartis and an expert on public health, has also expressed deep concern over the epidemic while speaking highly of the control and prevention measures put in place by the Chinese government.
"The disease is fatal in severe cases, and traditional medical solutions are mainly aimed to elevate platelet amounts to a safe level and reduce or avoid bleeding prove limited efficacy for some patients," said Chen Yu, executive director of the Hematological Department of the north campus of Ruijin Hospital Affiliated with the Shanghai Jiaotong University School of Medicine, during an event held by Novartis Oncology (China) at the ongoing China International Import Expo on Thursday.
Novartis Oncology showcased an innovative therapy in treating the disease.
Novartis said that it has introduced innovative drugs into the China market at a faster pace – one to three new products or new indications – over the last three years, and at least 25 drugs treating tumors have been available in the country.
To address eye health in China, Novartis signed a series of strategic collaboration agreements with local hospitals and foundations during the ongoing China International Import Expo on Wednesday.
Novartis also signed a collaboration agreement with the Eye Hospital affiliated with Shandong University of Traditional Chinese Medicine and Shandong Provincial Light Charity Foundation to focus on the eye health of diabetes patients in the province.
Swiss pharmaceutical company Novartis and China's internet giant Tencent jointly announced the official launch of an online long-term disease management platform for heart patients during the ongoing China International Import Expo on Wednesday.
Novartis said it is committed to bringing innovative therapies and services for the wellbeing of patients in China, and the innovation in the application of big data technology and digitalization will be a focus.
Company plans to tap unmet medical needs with innovative NDAs in ChinaSwiss pharmaceutical giant Novartis AG plans to submit applications for 50 innovative drugs focusing on unmet medical needs in China by 2023, riding the wave of streamlined and accelerated new drug approvals in the country.
Most of the drugs will target major diseases plaguing Chinese patients such as cardiovascular, eye and respiratory diseases, and tumors, John Tsai, head of global drug development and chief medical officer for Novartis, said in an interview with China Daily in Shanghai on Thursday.
Such a pace also derives from Novartis' robust pipeline of drugs and its commitment to the Chinese market, which brought into being an end-to-end research group consisting of 700 scientists from discovery, translational research, to development research based in Shanghai and Beijing to advance treatments with a focus on patients in China, Tsai explained.
Tencent and Novartis International AG signed a partnership agreement last week that brings together artificial intelligence, social platforms, technology and innovation for the benefit of patients with chronic diseases in China.
Ding Ke, vice-president of Tencent, and Yin Xudong, president of Novartis Pharmaceuticals Region APMA (Asia, Pacific, Middle East and Africa) and Novartis China, signed the memorandum on behalf of both parties.
As a leading global healthcare company powered by advanced therapy platforms and data science, Novartis is committed to innovative science, exploring the use of technology to provide new treatment options for patients, and developing strategic partnerships with the health technology ecosystem.
""Novartis' mission is to reimagine medicine to improve and extend people's lives.
Amid rising challenges in the healthcare sector, we believe innovative science along with digital approaches will help address some of society's challenging healthcare issues," said Yin Xudong, president of Novartis Pharmaceuticals Region APMA and Novartis China.
The collaboration between Tencent and Novartis creates a new opportunity for both parties to further leverage their expertise for the benefit of patients in China and potentially expand globally in the future.
Swiss pharmaceutical giant Novartis AG is looking to further tap into China's healthcare market by bringing more innovative drugs, while enhancing collaborations with local biotech and technology companies to further digital transformation of healthcare, a top company official said.
Vas Narasimhan, CEO of Novartis, said he expects China to "become one of the top three markets for Novartis by sales in the coming years".
"Now China's regulatory timelines are at the same level of what we see in the United States or in Europe," Narasimhan said, adding that Novartis got nine new medicines approved in China in the past two years alone, at a pace faster than ever.
Novartis, which spends more than $9 billion on research and development every year, runs an innovation hub in Shanghai, with an investment of $1 billion.
The CEO said Novartis is also engaging with Chinese regulators and local partners to bring cell and gene therapies to China, which have been heralded as a breakthrough in treating many intractable illnesses.
Last September, Novartis announced a deal with Shanghai-based biotech company Cellular Biomedicine Group, for manufacturing Kymriah, a CAR-T cell therapy, or chimeric antigen receptor cell therapy, treatment for cancer.
Kymriah has already been approved in Europe, Canada, and Australia and Novartis is looking to bring the same to China soon.
In addition to 40 biotech companies that Novartis currently has partnerships with, the company is also planning partnerships with technology companies in China.
The CEO took the helm at Novartis last year and has envisioned a focused medicines company that's powered by data sciences and digital technologies and has launched a number of initiatives to transform Novartis while reshaping the healthcare sector using digital technologies.
BT China's official website shows that its clients within China include multinational corporations like P&G, Novartis, ABInbev, PepsiCo etc, also Chinese multinational companies like Huawei, Air China, ZTE and Sinopec.
Swiss pharmaceutical company Novartis on Tuesday held a seminar to review progress of its ongoing carbon-sink forestry project in Sichuan province.
Present at the meeting were Frank Eggmann, Swiss consul-general in Chengdu; Liu Hongbao, director-general of the Sichuan Forestry and Grassland Administration; Yang Chunping, a researcher with the Institute of Economic System and Management of the National Development and Reform Commission, and Chen Xiaojing, vice president of Novartis Group (China).
Following similar carbon-sink projects in Argentina and Mali, Novartis in 2010 brought the carbon offset project to the Liangshan Yi autonomous prefecture in Sichuan.
"The Novartis carbon-sink forestry project in Sichuan is the first carbon-sink forestry project carried out in direct collaboration with a multinational company inxa0 China," said Liu Hongbao, director-general of the Sichuan Forestry and Grassland Administration.
Related technical integration and demonstration projects have also been launched this year in the context of the Novartis carbon-sink Project, which are expected to serve as templates for the development of the green and low carbon economy," he said.
"A further 30-50 years of careful forest management is needed for the Novartis carbon-sink forestry project in Sichuan to make its full impact," said Chen Xiaojing, vice president of Novartis Group (China).
Novartis is willing to join hands with the government and society in contributing to sound environmental stewardship.
This is a part of the Novartis' environment sustainability agenda and its long-standing commitment to China," she said.
Novartis Group China, an affiliate of the Swiss healthcare giant, is displaying its groundbreaking medicines and technologies at CIIE, including a number of innovative medicines for heart failure, respiratory disease, blood diseases, lung cancer, kidney cancer and breast cancer.
"CIIE is an international trade-exchange platform, and we value the opportunity to bring Novartis' diversified products and globally cutting-edge healthcare solutions to Chinese people," said Yin Xudong, president of Novartis Group China.
Name: Alex GorskyAge: 57EducationBachelor of Science degree from US Military Academy at West Point, New YorkMaster of Business Administration degree from The Wharton School of the University of PennsylvaniaCareer2012: CEO and chairman of Johnson & Johnson2011: Vice-chairman of Johnson & Johnson's executive committee2009: Worldwide chairman of the medical devices and diagnostics segment of Johnson & Johnson2008: Group chairman of Ethicon Inc of Johnson & Johnson2004: Head of pharmaceuticals business of Novartis Pharmaceuticals Corp North America2003: Group chairman of Johnson & Johnson's pharmaceuticals business in Europe, the Middle East and Africa2001: President of Janssen Pharmaceutica1988: Sales representative at Janssen Pharmaceutica
The winners are AIA China, Baxter (China) Investment, Becton Dickinson Medical Devices, CIFI Group, HNA Holding Group, Infinitus, McDonald's China, MSD China, Novartis Group China, Shanghai Disney Resort, Starbucks China, Taikang Pension & Insurance, The Ritz-Carlton Hotels China, and Wanhua Chemical Group.
cn]GSK Consumer Healthcare, one of world's largest consumer healthcare companies after its merger with Novartis' over-the-counter business in 2015, is riding the tide of China's thriving healthcare sector.
The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Switzerland in this October 22, 2013 file photo.
xa0 [Photo/Agencies]Swiss pharma giant Novartis AG plans to make big inroads into China's oncology market by bringing two new cutting edge cancer drugs to the country, as demand in the country for drugs to treat the disease continues to rise.
The new products launched by Novartis are Votrient and Jakavi, which received approval by the China Food and Drug Administration in the last couple of months.
"Every year 2.8 million people in China die from cancer," said Bruno Strigini, chief executive officer of Novartis Oncology.
"Novartis' Strigini said China was one of his group's key strategic markets.
In mid 2016, Novartis opened a research and development campus in Shanghai, which mainly targets various types of cancer that occur frequently in China and other regions of Asia.
As early as in 2007, Novartis established its institute for biomedical research in Shanghai, still in operation a decade later.
"The research and development campus, along with the institute for biomedical research in Shanghai, targets diseases that are prevalent in Asia," said Didier Dargent, general manager of Novartis Oncology (China).
In recent years, Novartis has seen strong performance in China, both in terms of drug approvals and business growth, and this year is off to an auspicious start.
Just a few days before Chinese New Year, 14 Novartis medicines and indications were included in the national drug reimbursement list and our major breast cancer drug received regulatory approval.
This ultimately rewards innovation and encourages Novartis to bring more innovative medicines to the China market.
BRINDLE: Novartis has been a beneficiary of China's reform and opening-up.
We anticipate that China will be Novartis's second-largest market by 2024 and central to our global growth strategy for the next 10 years.
Dan Brindle, president of Novartis Group China, said China's strong commitment to building an ecosystem that is supportive of business and innovation will provide further confidence to investors, and help companies such as Novartis to accelerate the delivery of innovative medicines to the China market.
Dan Brindle, president of Novartis Group China, expects China to become the company's second-largest market by 2025.
"We have benefited from China's ongoing economic reforms and opening-up policies," he said, adding that he looks forward to expanding Novartis' partnerships with the local healthcare ecosystem to bring the company's latest innovations to Chinese patients.
China has been carrying out higher-level opening-up with the pursuit of win-win collaboration, which is set to bring new vigor to the global economy, said Daniel Brindle, president of Novartis Group, China.
Application of digital tools has also helped Swiss multinational pharmaceutical company Novartis to launch new drugs and maintain strong growth in China despite the COVID-19 epidemic, according to company's chairman Joerg Reinhardt.
Reinhardt said that Novartis has benefited from China's broader reforms and opening-up, which have become "an integral part of the Chinese economy".
The country's continued efforts in healthcare reforms, and its economic resilience, which is especially noticeable since the epidemic, have provided Novartis adequate confidence to maintain its long-term strategy and commitment to China, he said.
Nearly half of such agreements and joint projects were signed or carried out together with pharmaceutical MNCs, including AstraZeneca, Novartis, Pfizer and Omron.
"Daniel Brindle, the president of Novartis China, said that the CIIE has provided Novartis, which has participated in the CIIE since the inaugural edition, with an "excellent display platform" and built a bridge for communication with the government, experts, and patient groups, which paves the way for projects that have long-term strategic significance for its development in China.
During the first half of 2022, Chinese pharmaceutical enterprises out-licensed 26 drug pipelines to foreign enterprises, including multinational giants like Roche, Novartis, Merck and Eli Lilly.
Those deals include Chinese enterprise BeiGene's two anti-cancer asset out-license agreements with Novartis, which were respectively worth up to $2.2 billion and $2.9 billion.
Novartis and the Lecheng pilot zone administration also signed a strategic cooperation memorandum at CIIE, aiming to leverage real-world data to verify the efficacy and safety of drugs, and thereby help drug regulatory authorities make decisions and accelerate the approval of innovative medicines.
Novartis and Shanghai Zhangjiang Group signed a memorandum of understanding during the CIIE to set up the Novartis China Life Sciences Open Innovation Platform.
For Swiss pharmaceutical company Novartis, the new arrangement ensures that China teams provide input to its global development programs much earlier.
At the same time, we consider feedback from other major global regulators in designing our phase 3 studies," said Vas Narasimhan, Novartis CEO.
Johan Kahlstroem, head of the cardiovascular, renal and metabolism business unit at Novartis Pharma (China), said 100 percent of its clinical trials in relevant disease areas in China take place simultaneously with global trials today.
The Chinese startup is the second drug developer worldwide to engage in clinical development of an SHP2 inhibitor drug candidate, following Novartis.
这家中国初创公司是全球第二家涉足SHP2抑制剂药物候选物临床开发的制药企业，紧跟在诺华之后。
未经许可，严禁转发。QQ交流群：688169419